Patent Litigation Update: GSK/PTO Fight Continues; Alzheimer's Institute Sues Pfizer
Battle over patent rules continues: The U.S. Court of Appeals for the Federal Circuit agreed to rehear en banc a suit seeking to block Patent and Trademark Office rules. A three-judge panel found in March that rules to limit the number of continuation applications are invalid but those limiting requests for continued examination and requiring support documentation are within the scope of PTO's rulemaking authority ("The Pink Sheet," March 30, 2009). Inventor Triantafyllos Tafas and GlaxoSmithKline sued to block the rules. The hearing before the full court is scheduled for Oct. 7. The case is being closely watched by the pharmaceutical and biotech industries, which filed amicus briefs opposing the rules
You may also be interested in...
The drug industry won a partial victory in its battle with the U.S. Patent and Trademark Office over rules to limit certain patent filings
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials